2
项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的临床试验A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 65 Years of Age
The goal of Phase 3 Study is Comparing the Safety and Immune Response of Three Batches of a COVID-19 and Flu Combination Vaccine in Seniors Aged 65+
A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ≥ 65 Years of Age.
The goal of this Phase 3 study is to compare the effectiveness, safety, and side effects of the CIC vaccine with approved flu vaccines and the Novavax COVID-19 Vaccine with adjuvant.
100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的临床结果
100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的转化医学
100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的专利(医药)
100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的药物交易